CAR-T Cell Therapy Package for Multiple Myeloma in Beijing, China by Bioocus Biotech

CAR-T cell therapy represents a significant advancement in the treatment of multiple myeloma, and Bioocus Biotech in Beijing, China, stands at the forefront of this cutting-edge treatment. This innovative therapy involves modifying a patient's own T-cells to target and destroy cancer cells, offering a promising option for those with multiple myeloma who have not responded well to conventional treatments. Bioocus Biotech offers an exceptional environment for receiving CAR-T cell therapy.

The center’s commitment to integrating the latest technology with personalized patient care enhances the overall treatment experience. Patients choosing this therapy benefit from both the advanced medical infrastructure of Beijing and the specialized expertise of Bioocus Biotech’s healthcare professionals.

Cost of CAR-T Cell Therapy for Multiple Myeloma in Beijing, China

You can get CAR-T Cell Therapy Package for Multiple Myeloma in Beijing, China by Beijing Bioocus with the price starts at $100,000. Please refer to our price list table below:

Location	Cost in USD
Beijing China	$100,000

Note: price may change and vary depends on complexity of procedures and patient conditions. Click free quote button below to learn more.

5 Advantages of Choosing CAR-T Cell Therapy in Beijing, China

• World-Class Medical Facilities: Beijing boasts some of the most advanced medical facilities in the world, equipped with cutting-edge technology and staffed by highly skilled professionals.

• Experienced Medical Team: The medical team at Bioocus Biotech includes experts in CAR-T cell therapy and multiple myeloma, ensuring that patients receive care from professionals with extensive experience and specialized knowledge.

• Affordable Healthcare Costs: Compared to many Western countries, healthcare costs in Beijing are generally more affordable.

• Comprehensive Care: Bioocus Biotech provides a holistic approach to treatment, integrating CAR-T cell therapy with comprehensive support services.

• Cultural and Historical Experience: Beyond the medical benefits, patients in Beijing have the opportunity to experience the rich cultural and historical heritage of China.

Introduction to BCMA CAR-T Therapy for Multiple Myeloma Multiple myeloma (MM) is a hematologic malignancy characterized by the proliferation of malignant plasma cells. Despite advancements in treatments, MM remains largely incurable, particularly in relapsed or refractory cases. B-cell maturation antigen (BCMA) has emerged as a promising target for chimeric antigen receptor (CAR) T-cell therapy. This introduction provides an overview of BCMA CAR-T therapy, its efficacy, safety, and potential challenges. Mechanism of CAR-T Therapy for BCMA BCMA is a protein expressed on the surface of plasma cells and myeloma cells but not on most other cell types, making it an ideal target for CAR-T cell therapy. CAR-T cells are genetically engineered T cells that express receptors specific to BCMA, allowing them to recognize and kill BCMA-expressing myeloma cells. High Efficacy and Safety A systematic review and meta-analysis revealed that BCMA CAR-T cell therapy shows high efficacy, with an overall response rate of 80.5% and complete response rate of 44.8%. However, cytokine release syndrome (CRS) occurred in 80.3% of patients, and 10.5% experienced neurotoxicity. These findings highlight both the potential and the risks associated with the therapy. Clinical Activity and Response Rates A phase I study of BCMA-specific CAR-T cells in relapsed/refractory MM patients demonstrated significant clinical activity, with responses in 64% of patients at the highest dose level. The study also noted manageable toxicities, including CRS and neurotoxicity Mechanisms of Resistance Research indicates that while BCMA CAR-T therapy can achieve deep and durable remissions, many patients eventually relapse. A study found that resistance mechanisms include loss of BCMA expression on tumor cells, suggesting the need for strategies to prevent or overcome such resistance Cody Insley Campbell's Case Patient: Cody Insley Campbell, Canadian Condition: Multiple Myeloma Treatment: BCMA CAR-T therapy Outcome: Cody received BCMA CAR-T therapy in China after 11 years of illness with limited options in Canada. The treatment showed unprecedented results in just 30 days, significantly improving his condition. Cody expressed gratitude for the compassionate care received and encouraged others to take risks for potential rewards.

CAR-T Cell Therapy Package Inclusions

• Pre-Treatment Consultation: Includes a detailed discussion with the medical team to evaluate the patient’s suitability for CAR-T cell therapy.

• Leukapheresis Procedure: This is the initial step in CAR-T cell therapy where T-cells are collected from the patient’s blood.

• Genetic Engineering of T-Cells: The collected T-cells are sent to the laboratory for modification to produce CARs.

• CAR-T Cell Infusion: The modified T-cells are reintroduced into the patient’s bloodstream. This infusion is carefully managed to maximize the effectiveness of the therapy.

• Post-Treatment Monitoring and Support: Includes follow-up appointments and care to monitor the patient’s response to the therapy.

CAR-T Cell Therapy Package Exclusions

• Travel and Accommodation Costs: The package does not include expenses related to traveling to Beijing or accommodation during the treatment period.

• Pre-Treatment Testing Costs: While initial consultations are included, any additional pre-treatment testing or diagnostic procedures not specifically mentioned in the package are not covered.

• Extended Stay Expenses: Any costs incurred due to an extended stay beyond the planned treatment period, including additional medical care or extended accommodation, are not included in the package.

• Alternative Therapies: The package focuses specifically on CAR-T cell therapy and does not cover costs for alternative or complementary therapies that a patient may choose to pursue.

• Personal Expenses: Any personal expenses, including meals, local transportation, and leisure activities, are not included in the package. Patients should plan for these costs independently.

CAR-T Cell Therapy for Multiple Myeloma Pre-Op Tests

• Blood Tests: Comprehensive blood tests are performed to evaluate the patient’s overall health and ensure that they are suitable candidates for CAR-T cell therapy.

• Bone Marrow Biopsy: This test is used to assess the extent of multiple myeloma and evaluate the bone marrow’s condition.

• Imaging Studies: MRI, CT scans, or PET scans are conducted to visualize the extent of the disease and monitor any existing tumors.

• Cardiac Evaluation: A thorough cardiac evaluation is performed to ensure that the patient’s heart is healthy enough to handle the stress of the therapy.

• Lung Function Tests: These tests assess the function of the lungs to ensure that the patient can tolerate the therapy without respiratory complications.

CAR-T Cell Therapy Doctor in Beijing, China

At the forefront of Beijing Bioocus Biotech Limited stands Dr. Daopei Lu, our distinguished Chief Scientist, whose international acclaim in the field of hematology is unmatched. Dr. Lu's extraordinary leadership and groundbreaking research in cellular immunotherapy have significantly advanced the understanding and treatment of cancer. His profound expertise in cellular mechanisms and immunological responses has led to the development of innovative therapies that offer new avenues of hope for patients around the globe. Under Dr. Lu's visionary guidance, Bioocus Biotech has become a beacon of progress in cancer treatment, pushing the boundaries of scientific knowledge.

Is CAR-T Cell Therapy Right for You?

• Eligibility Assessment: CAR-T cell therapy is generally considered for patients with multiple myeloma who have not responded well to other treatments.

• Potential Benefits: The therapy offers the potential for significant improvements in symptoms and disease control, particularly for those who have exhausted other treatment options.

• Possible Risks: As with any advanced therapy, there are risks and potential side effects, including cytokine release syndrome and neurotoxicity.

• Previous Treatment History: Patients with a history of prior treatments may need to meet specific criteria to qualify for CAR-T cell therapy.

• Support System: A strong support system and good general health can positively influence the success of CAR-T cell therapy.

What to Expect During the CAR-T Cell Therapy for Multiple Myeloma

• Initial Preparation: Expect a thorough preparation phase that includes pre-treatment tests, consultations with your medical team, and discussions about the therapy process. This preparation ensures you are ready for the CAR-T cell therapy.

• Infusion Process: During the infusion of modified T-cells, you will be monitored closely for any immediate reactions. The process is typically performed in a controlled environment to ensure safety and effectiveness.

• Side Effect Management: Be prepared for potential side effects, such as fever or flu-like symptoms, and discuss how they will be managed. Your medical team will provide support and treatment to address any issues that arise.

• Recovery and Monitoring: After the infusion, expect a period of recovery and close monitoring to track your response to the therapy and manage any side effects. Regular follow-up appointments are crucial for assessing progress and ensuring the best outcomes.

• Post-Treatment Care: Ongoing care and support are provided to help you adjust to any changes and maintain your health. This includes managing any long-term effects and ensuring a smooth transition back to daily life.

FAQs (Frequently Asked Questions)

1. What is CAR-T cell therapy for multiple myeloma?

CAR-T cell therapy is an advanced treatment that involves modifying a patient's T-cells to target and destroy cancer cells. For multiple myeloma, this therapy specifically targets myeloma cells to improve patient outcomes when other treatments have failed.

2. How long does the CAR-T cell therapy process take?

The CAR-T cell therapy process typically involves several stages, including cell collection, genetic modification, infusion, and recovery. Overall, the entire treatment process, from initial consultations to post-treatment monitoring, can span several weeks.

3. What are the common side effects of CAR-T cell therapy?

Common side effects may include fever, fatigue, and flu-like symptoms. More severe effects can include cytokine release syndrome and neurotoxicity. Your medical team will monitor these closely and manage any side effects that arise.

4. How effective is CAR-T cell therapy for treating multiple myeloma?

CAR-T cell therapy has shown promising results for treating multiple myeloma, particularly for patients who have not responded to other treatments. Many patients experience significant reductions in symptoms and extended periods of remission.

5. What should I expect during my stay in Beijing for treatment?

During your stay in Beijing, you will undergo the CAR-T cell therapy at Bioocus Biotech. Expect comprehensive care, including pre-treatment tests, the infusion procedure, and post-treatment monitoring. Additionally, you will have the opportunity to experience the cultural and historical aspects of Beijing.

Get FREE QUOTE for CAR-T Cell Therapy in Beijing, China at PlacidWay!

Ready to take the next step towards advanced treatment for multiple myeloma? Book your consultation with PlacidWay Medical Tourism today to learn more about the CAR-T cell therapy package at Bioocus Biotech in Beijing, China. Our team is here to provide detailed information and assist you throughout the process.